Shares of HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $20.82, but opened at $19.90. HUTCHMED shares last traded at $19.73, with a volume of 12,115 shares trading hands.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the stock. StockNews.com lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a research report on Thursday, July 18th. The Goldman Sachs Group lifted their price target on shares of HUTCHMED from $17.00 to $19.00 and gave the stock a "neutral" rating in a research report on Thursday, August 1st.
Check Out Our Latest Stock Report on HUTCHMED
HUTCHMED Stock Performance
The stock has a 50 day moving average of $18.10 and a two-hundred day moving average of $18.19. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.
Hedge Funds Weigh In On HUTCHMED
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. M&G Plc acquired a new position in shares of HUTCHMED in the 1st quarter valued at about $4,458,000. Rhumbline Advisers increased its stake in HUTCHMED by 8.1% in the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company's stock valued at $129,000 after buying an additional 564 shares during the period. Hennion & Walsh Asset Management Inc. lifted its position in HUTCHMED by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 61,887 shares of the company's stock worth $1,060,000 after buying an additional 4,877 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of HUTCHMED by 54.9% during the 1st quarter. BNP Paribas Financial Markets now owns 42,926 shares of the company's stock valued at $721,000 after buying an additional 15,221 shares during the period. Finally, Hsbc Holdings PLC boosted its stake in shares of HUTCHMED by 821.2% during the 4th quarter. Hsbc Holdings PLC now owns 206,544 shares of the company's stock valued at $3,720,000 after buying an additional 184,123 shares during the period. Institutional investors and hedge funds own 8.82% of the company's stock.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
See Also
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
